EMERYVILLE, Calif., April 7, 2021 /PRNewswire/ — Amyris, Inc., (Nasdaq: AMRS) (“Amyris”), a number one artificial biotechnology firm lively within the Clear Well being and Magnificence markets by its shopper manufacturers and a prime provider of sustainable and pure elements, right now introduced the graduation of a proposed underwritten public providing of shares of its frequent inventory.
Amyris is conducting a resale of inventory on behalf of its present stockholders, DSM Worldwide B.V. and associates of Vivo Capital LLC (the promoting stockholders). The promoting stockholders intend to supply an mixture of $150.0 million of shares of Amyris’s frequent inventory. Amyris won’t obtain any proceeds from the sale of the shares by the promoting stockholders. Moreover, Amyris intends to supply $100.0 million of shares of its frequent inventory to assist its continued development.
The promoting stockholders and Amyris count on to grant the underwriters a 30-day choice to buy as much as an extra $37.5 million of shares of Amyris’s frequent inventory on the public providing worth, much less underwriting reductions and commissions. The proposed providing is topic to market and different circumstances, and there will be no assurance as as to whether or when the providing could also be accomplished, or as to the precise dimension or phrases of the providing.
J.P. Morgan Securities LLC and Cowen and Firm, LLC are appearing because the joint bookrunning managers for the proposed providing.
The general public providing is being made pursuant to an computerized shelf registration assertion on Kind S-3 that was filed by Amyris with the U.S. Securities and Change Fee (the “SEC”) and robotically grew to become efficient upon submitting. The proposed providing is being made solely by the use of an efficient shelf registration assertion, together with a preliminary prospectus and remaining prospectus, copies of which can be obtained, when accessible, from J.P. Morgan Securities LLC, c/o Broadridge Monetary Options, 1155 Lengthy Island Avenue, Edgewood, NY 11717, by phone at (866) 803-9204, or by e-mail at firstname.lastname@example.org; or Cowen and Firm, LLC, c/o Broadridge Monetary Options, Attn: Prospectus Division, 1155 Lengthy Island Avenue, Edgewood, NY 11717, by phone at (833) 297-2926, or by e-mail at PostSaleManualRequests@broadridge.com.
This press launch shall not represent a suggestion to promote or the solicitation of a suggestion to purchase, nor shall there be any sale of those securities in any state or jurisdiction during which such provide, solicitation or sale can be illegal previous to registration or qualification underneath the securities legal guidelines of any such state or jurisdiction.
Amyris (Nasdaq: AMRS) is a science and expertise chief within the analysis, improvement and manufacturing of sustainable elements for the Clear Well being & Magnificence and Flavors & Fragrances markets. Amyris makes use of a powerful array of unique applied sciences, together with state-of-the-art machine studying, robotics and synthetic intelligence. Our elements are included in over 3,000 merchandise from the world’s prime manufacturers, reaching greater than 200 million customers. Amyris is proud to personal three shopper manufacturers – all constructed round its No Compromise® promise of unpolluted elements: Biossance® clear magnificence skincare, Pipette® clear child skincare and Purecane™, a zero-calorie sweetener naturally derived from sugarcane. Amyris, the Amyris brand, No Compromise, Biossance, Pipette, and Purecane are logos or registered logos of Amyris, Inc. within the U.S. and/or different nations.
Use of forward-looking statements
This press launch comprises “forward-looking statements” throughout the which means of, and made pursuant to the Securities Act of 1933, as amended, the Securities Change Act of 1934, as amended, and secure harbor provisions of the Non-public Securities Litigation Reform Act of 1995, together with, however not restricted to, statements concerning the phrases of the proposed public providing, together with the promoting stockholders’ and our expectations with respect to granting the underwriters a 30-day choice to buy extra shares, and the completion, timing, dimension and dilutive impression of the proposed public providing. These forward-looking statements could also be accompanied by such phrases as “goal,” “anticipate,” “consider,” “might,” “estimate,” “count on,” “forecast,” “objective,” “intend,” “might,” “may,” “plan,” “potential,” “potential,” “will,” “would,” and different phrases and phrases of comparable which means. These statements contain dangers and uncertainties that would trigger precise outcomes to vary materially from these mirrored our public filings, together with with out limitation, dangers that are exterior of our full management; dangers related to present and potential delays, work stoppages, or provide chain disruptions attributable to the coronavirus pandemic; and the opposite dangers and uncertainties which might be described within the Threat Components part in our Annual Report on Kind 10-Okay filed with the SEC on March 5, 2021, and different studies as filed with the SEC, the preliminary prospectus complement associated to the proposed public providing and subsequent filings with the SEC. We undertake no obligation to publicly replace any forward-looking assertion, whether or not written or oral, that could be made occasionally, whether or not because of new data, future developments or in any other case.
View authentic content material to obtain multimedia:http://www.prnewswire.com/news-releases/amyris-announces-proposed-public-offering-secondary-and-primary-of-common-stock-301264570.html
SOURCE Amyris, Inc.